Meeder Asset Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Meeder Asset Management’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,285	Closed	-$4K	–	1924
2018 Q3	$4K	Buy	3,285 +2,637	+407%	+$4.09K	﹤0.01%	1392
2018 Q2	$875	Buy	648 +160	+33%	+$245	﹤0.01%	1522
2018 Q1	$1K	Buy	488 +29	+6%	+$61	﹤0.01%	1540
2017 Q4	$1K	Buy	459 +161	+54%	+$407	﹤0.01%	1639
2017 Q3	$1K	Sell	298 -29	-9%	-$98	﹤0.01%	1611
2017 Q2	$1K	Sell	327 -612	-65%	-$2.02K	﹤0.01%	1624
2017 Q1	$3K	Sell	939 -1,261	-57%	-$4.9K	﹤0.01%	1335
2016 Q4	$10K	Buy	+2,200	New	+$9.08K	﹤0.01%	767

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meeder Asset Management's AST Position: Q4 2018 in Review

Meeder Asset Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 3,285 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in AST in Q4 2016 and held it in 8 quarters. The position peaked at $10K in Q4 2016. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

Meeder Asset Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
Meeder Asset Management sold 3,285 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $4K.
Meeder Asset Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2016 and held it in 8 quarters.
Meeder Asset Management's Asterias Biotherapeutics Inc. Series A position peaked at $10K in Q4 2016.
46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Meeder Asset Management's 13F filing for Q4 2018, filed 17 Jan 2019.